Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Liabilities from Discontinued Operations (2021 - 2023)

Insight Molecular Diagnostics (IMDX) has disclosed Liabilities from Discontinued Operations for 3 consecutive years, with 45000.0 as the latest value for Q4 2023.

  • Quarterly Liabilities from Discontinued Operations fell 97.76% to 45000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was 45000.0 through Dec 2023, down 97.76% year-over-year, with the annual reading at 45000.0 for FY2023, 97.76% down from the prior year.
  • Liabilities from Discontinued Operations hit 45000.0 in Q4 2023 for Insight Molecular Diagnostics, down from 90000.0 in the prior quarter.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 2005000.0 in Q4 2022 to a low of 45000.0 in Q4 2023.
  • Historically, Liabilities from Discontinued Operations has averaged 672833.33 across 3 years, with a median of 185500.0 in 2023.
  • Biggest five-year swings in Liabilities from Discontinued Operations: surged 31.39% in 2022 and later tumbled 97.76% in 2023.
  • Year by year, Liabilities from Discontinued Operations stood at 1526000.0 in 2021, then soared by 31.39% to 2005000.0 in 2022, then crashed by 97.76% to 45000.0 in 2023.
  • Business Quant data shows Liabilities from Discontinued Operations for IMDX at 45000.0 in Q4 2023, 90000.0 in Q3 2023, and 135000.0 in Q2 2023.